Validate Mitochondria-Lysosome Contact Site Dysfunction in PD

Validate Mitochondria-Lysosome Contact Site Dysfunction in PD

Background and Rationale

Mitochondria-lysosome contact sites (MCS) represent critical subcellular structures that facilitate organellar communication, lipid transfer, and mitophagy regulation. In Parkinson's disease (PD), mutations in GBA encoding glucocerebrosidase lead to glucosylceramide accumulation within lysosomes, fundamentally disrupting MCS architecture and function. This disruption creates a pathogenic cascade involving impaired mitophagy, defective alpha-synuclein clearance, and progressive neurodegeneration. The study employs a comprehensive validation approach using human iPSC-derived dopaminergic neurons from GBA-PD patients and age-matched controls. We will utilize advanced imaging techniques including super-resolution microscopy and electron tomography to quantify MCS morphology, frequency, and molecular composition. The experimental design incorporates functional assays measuring mitochondrial quality control, lysosomal enzyme activity, and alpha-synuclein aggregation dynamics.

...

Validate Mitochondria-Lysosome Contact Site Dysfunction in PD

Background and Rationale

Mitochondria-lysosome contact sites (MCS) represent critical subcellular structures that facilitate organellar communication, lipid transfer, and mitophagy regulation. In Parkinson's disease (PD), mutations in GBA encoding glucocerebrosidase lead to glucosylceramide accumulation within lysosomes, fundamentally disrupting MCS architecture and function. This disruption creates a pathogenic cascade involving impaired mitophagy, defective alpha-synuclein clearance, and progressive neurodegeneration. The study employs a comprehensive validation approach using human iPSC-derived dopaminergic neurons from GBA-PD patients and age-matched controls. We will utilize advanced imaging techniques including super-resolution microscopy and electron tomography to quantify MCS morphology, frequency, and molecular composition. The experimental design incorporates functional assays measuring mitochondrial quality control, lysosomal enzyme activity, and alpha-synuclein aggregation dynamics. Key innovations include real-time monitoring of organellar contacts using proximity-based labeling and development of MCS-specific functional readouts. VPS13D, a MCS-resident lipid transfer protein, serves as both a biomarker and therapeutic target, with pharmacological modulators tested for rescue potential. This validation study addresses a fundamental gap in understanding PD pathogenesis by directly linking lysosomal storage dysfunction to mitochondrial homeostasis failure through MCS disruption, providing mechanistic insights for therapeutic intervention targeting organellar communication networks.

This experiment directly tests predictions arising from the following hypotheses:

• Mitochondrial-Lysosomal Contact Site Engineering
• Mitochondrial Transfer Pathway Enhancement
• Lysosomal Calcium Channel Modulation Therapy
• Transcriptional Autophagy-Lysosome Coupling
• Autophagosome Maturation Checkpoint Control

Experimental Protocol

Phase 1 (Days 1-14): Generate iPSC-derived dopaminergic neurons from GBA-PD patients (n=6 lines) and controls (n=6 lines) using established protocols. Culture cells for 35 days to achieve mature neuronal phenotype. Phase 2 (Days 15-21): Transfect neurons with fluorescent markers (mitoGFP, LysoTracker Red, VPS13D-mCherry) using lipofectamine. Treat experimental groups with glucosylceramide (50μM) or vehicle control for 48h to model GBA dysfunction. Phase 3 (Days 22-25): Perform live-cell confocal microscopy capturing z-stacks every 30 seconds for 10 minutes. Quantify MCS using colocalization analysis (Manders coefficients) and proximity measurements (<150nm distance). Conduct transmission electron microscopy on fixed samples for ultrastructural MCS analysis. Phase 4 (Days 26-28): Execute functional assays including mitochondrial membrane potential (TMRM staining), lysosomal pH (LysoSensor), and glucocerebrosidase activity (4-methylumbelliferyl-β-D-glucopyranoside substrate). Measure alpha-synuclein aggregation using proximity ligation assay and Western blotting. Phase 5 (Days 29-35): Test VPS13D modulators (compound library screening at 1-10μM) for rescue effects on MCS formation and function. Perform RNA-seq analysis on treated samples to assess transcriptional responses. Statistical analysis using two-way ANOVA with Bonferroni correction, n≥100 cells per condition across biological replicates.

Expected Outcomes

• GBA-PD neurons will show 60-70% reduction in mitochondria-lysosome contact frequency compared to controls, with decreased contact duration (p<0.001)
• VPS13D protein levels will be reduced by 40-50% in GBA-PD neurons, correlating with MCS dysfunction (r>0.7, p<0.01)
• Glucosylceramide accumulation will cause 2.5-fold increase in lysosomal volume and 50% reduction in mitochondrial membrane potential
• Alpha-synuclein aggregate formation will increase 3-4 fold in GBA-PD neurons with concurrent 60% reduction in mitophagy flux
• VPS13D pathway modulators will restore MCS formation by 70-80% and reduce alpha-synuclein aggregation by 50%
• Electron microscopy will reveal structural MCS abnormalities with 40% fewer contact sites and altered membrane curvature in GBA-PD samples

Success Criteria

• Statistically significant reduction (≥50%) in MCS frequency in GBA-PD neurons vs controls with p<0.01
• Measurable VPS13D protein reduction (≥30%) correlating with MCS dysfunction (correlation coefficient >0.6)
• Demonstrated rescue of MCS phenotype (≥60% restoration) following VPS13D modulator treatment
• Quantifiable alpha-synuclein aggregation increase (≥2-fold) in GBA-PD samples with statistical significance p<0.05
• Ultrastructural validation of MCS defects using electron microscopy with ≥30% reduction in contact sites
• Reproducible results across ≥4 independent iPSC lines per group with consistent effect directions